Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H23N3O6S |
| Molecular Weight | 445.489 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](CO)OC1=CC(=CC(OC2=CC=C(C=C2)S(C)(=O)=O)=C1)C(=O)NC3=NN(C)C=C3
InChI
InChIKey=RIIDAVMUCMIWKP-AWEZNQCLSA-N
InChI=1S/C21H23N3O6S/c1-14(13-25)29-17-10-15(21(26)22-20-8-9-24(2)23-20)11-18(12-17)30-16-4-6-19(7-5-16)31(3,27)28/h4-12,14,25H,13H2,1-3H3,(H,22,23,26)/t14-/m0/s1
| Molecular Formula | C21H23N3O6S |
| Molecular Weight | 445.489 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 18:44:17 GMT 2025
by
admin
on
Tue Apr 01 18:44:17 GMT 2025
|
| Record UNII |
Z7H4089VLO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11525116
Created by
admin on Tue Apr 01 18:44:17 GMT 2025 , Edited by admin on Tue Apr 01 18:44:17 GMT 2025
|
PRIMARY | |||
|
752239-85-3
Created by
admin on Tue Apr 01 18:44:17 GMT 2025 , Edited by admin on Tue Apr 01 18:44:17 GMT 2025
|
PRIMARY | |||
|
Z7H4089VLO
Created by
admin on Tue Apr 01 18:44:17 GMT 2025 , Edited by admin on Tue Apr 01 18:44:17 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antihyperglycaemic, Pyridine; Mechanism of Action: Glucokinase stimulant; Highest Development Phases: Discontinued for Type 2 diabetes mellitus; Most Recent Events: 27 Jan 2011 Discontinued - Phase-II for Type-2 diabetes mellitus in Sweden (PO), 31 Jul 2008 Phase-II clinical trials in Type-2 diabetes mellitus in Sweden (PO), 31 Jul 2007 Phase-I clinical trials in Type-2 diabetes mellitus in Sweden (PO)
|
||
|
ACTIVE MOIETY |
AZD6370 was well tolerated and no safety concerns were raised. AZD6370 was rapidly absorbed and eliminated, and plasma concentration was proportional to dose. Both S-insulin and GIR increased following AZD6370 administration. The observed increase in GIR correlated with increasing AZD6370 area under the plasma concentration vs. time curve, demonstrating a dose-concentration-dependent pharmacodynamic effect. AZD6370 at doses of 50 and 80 mg had similar effects to short-acting insulin 4 U on peripheral S-insulin levels but greater effects on GIR, suggesting an effect beyond the increase of peripheral S-insulin levels at lower doses.
|
